Expression of COX-1, COX-2, 5-LOX and
Arachidonic acid
Aspirin exacerbated respiratory disease
Asthma
Cyclooxygenases
Leukotrienes
Lipoxygenases
Nasal polyps
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
08
2019
accepted:
10
12
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
epublish
Résumé
Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance. We sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 ( Tissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and We observed a stronger expression of 5-LOX and The AA-metabolizing enzymes and the
Sections du résumé
BACKGROUND
BACKGROUND
Aspirin exacerbated respiratory disease (AERD) is a disease of the upper and lower airways. It is characterized by severe asthma, chronic sinusitis with nasal polyps (CRSwNP) and intolerance towards nonsteroidal analgesics (NSAR). Arachidonic acid (AA) metabolites play an important role in the pathogenesis of AERD. It is still unknown, whether metabolism of AA is comparable between the upper and lower airways as well as between patients with and without NSAR intolerance.
OBJECTIVE
OBJECTIVE
We sought to analyze differences in the expression of cyclooxygenases type 1 and 2 (COX-1, COX-2), arachidonate 5-lipoxygenase (5-LOX) and cysteinyl leukotriene receptor type 2 (
METHODS
METHODS
Tissue biopsies from nasal polyps and bronchial mucosa were obtained during surgical treatment of nasal polyps by endonasal functional endoscopic sinus surgery (FESS) under general anesthesia from intubated patients. Immunohistochemistry was used to analyze the expression of COX-1, COX-2, 5-LOX and
RESULTS
RESULTS
We observed a stronger expression of 5-LOX and
CONCLUSIONS
CONCLUSIONS
The AA-metabolizing enzymes and the
Identifiants
pubmed: 31889962
doi: 10.1186/s13223-019-0395-5
pii: 395
pmc: PMC6933683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Allergy Clin Immunol. 2004 Oct;114(4):814-9
pubmed: 15480320
Proc Natl Acad Sci U S A. 1984 Aug;81(15):4922-5
pubmed: 6087352
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
Clin Exp Allergy. 1998 Sep;28(9):1145-52
pubmed: 9761019
Clin Exp Allergy. 2002 Oct;32(10):1484-90
pubmed: 12372129
J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):837-42
pubmed: 9215253
Am Rev Respir Dis. 1988 Apr;137(4):847-54
pubmed: 2451458
J Allergy Clin Immunol. 2005 Feb;115(2):316-22
pubmed: 15696087
Clin Exp Allergy. 1998 Mar;28(3):278-83
pubmed: 9543076
Ann Otol Rhinol Laryngol. 2002 Jan;111(1):61-7
pubmed: 11800371
Clin Exp Allergy. 2009 Jun;39(6):820-8
pubmed: 19364335
Clin Exp Allergy. 2002 Mar;32(3):339-42
pubmed: 11940059
Respir Res. 2014 Aug 26;15:100
pubmed: 25155136
Nature. 1999 Jun 24;399(6738):789-93
pubmed: 10391245
Int Arch Arbeitsmed. 1966 Apr 13;22(1):77-94
pubmed: 5957910
Allergy Asthma Immunol Res. 2014 Jul;6(4):288-95
pubmed: 24991451
Am J Respir Cell Mol Biol. 1997 Dec;17(6):683-90
pubmed: 9409555
J Allergy Clin Immunol. 1997 Sep;100(3):283-7
pubmed: 9314336
J Allergy Clin Immunol. 2015 Mar;135(3):676-81.e1
pubmed: 25282015
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 2):S137-41
pubmed: 10673243
Am Rev Respir Dis. 1992 Jan;145(1):65-9
pubmed: 1309968
Auris Nasus Larynx. 2016 Jun;43(3):304-8
pubmed: 26527517
Lancet. 1993 Apr 17;341(8851):989-90
pubmed: 8096945
J Clin Invest. 1998 Feb 15;101(4):834-46
pubmed: 9466979
J Pathol. 2006 Jul;209(3):392-9
pubmed: 16583357
Agents Actions Suppl. 1987;21:195-202
pubmed: 3118663
J Allergy Clin Immunol. 1993 Feb;91(2):580-98
pubmed: 8436774
Physiol Rev. 1999 Oct;79(4):1193-226
pubmed: 10508233
Trends Immunol. 2004 Jan;25(1):40-6
pubmed: 14698283
Am J Rhinol. 2005 Mar-Apr;19(2):111-6
pubmed: 15921208
Curr Opin Pulm Med. 2004 Jan;10(1):51-6
pubmed: 14749606
J Allergy Clin Immunol. 2002 May;109(5):824-30
pubmed: 11994707
J Biol Chem. 2000 Sep 29;275(39):30531-6
pubmed: 10851239
J Allergy Clin Immunol. 1989 Jul;84(1):26-33
pubmed: 2666482
Eur Respir J. 2018 Oct 25;52(4):
pubmed: 30190271
Ann Allergy Asthma Immunol. 2005 Jun;94(6):652-7
pubmed: 15984597
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):579-87
pubmed: 16785401
Eur Respir J. 2000 Sep;16(3):432-6
pubmed: 11028656
Ann Intern Med. 1968 May;68(5):975-83
pubmed: 5646829